Name: SRT1720 HCl
Brand: Selleck Chemicals
SKU: S1129
Rating: 5 (154 reviews)

CAS No. 1001645-58-4

Selleck's SRT1720 HCl has been cited by 154 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Related Compound Libraries

Other Sirtuin Products

Download Inhibitor Catalog

Sirtuin Signaling Pathway Map

Biological Activity

Description

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

Targets

SIRT1 ^[1]
(Cell-free assay)

0.16 μM(EC50)

In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. ^[1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

CACs	MXjGeY5kfGmxbjDBd5NigQ>?	MnXzOOKh\|ryP	Ml\ON\|DDqG2rbh?=	MX3EUXNQ	NHLM[YlqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?=	M2jjZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW0NVA1Lz5{NkK1OFExPDxxYU6=
MC3T3-E1	MUPGeY5kfGmxbjDBd5NigQ>?	M4rIWVExKML3TdMg	MXOxJIg>		NUXKeGxHemWmdXPld{B1cGViVFfGMe6zNXO2aX31cIF1\WRiVlXHSkBz\WynYYPlJIlvKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=>	M4HpRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
MC3T3-E1	NEnqN2tHfW6ldHnvckBCe3OjeR?=	M3L0fVExKML3TdMg	M{fhTVEzKGh?		MXTy[YR2[2W\|IITo[UBXTUeIIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMhe3SrbYXsZZRm\CCkeTDUS2Yu\|rJ?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nkm3PEc,OjZzM{[5O\|g9N2F-
MC3T3-E1	MoXxSpVv[3Srb36gRZN{[Xl?	M4fVfVIxKM7:TR?=	NUfFPHFiOSCq		MVXzeZBxemW\|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N	M4DiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
WE-68	MUjBdI9xfG:\|aYOgRZN{[Xl?	MojtNE0zPCEQvF2=	NUXncnRzOjRiaB?=		Mln6bY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk>	NInRS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
SK-ES-1	NH3rb3BCeG:ydH;zbZMhSXO\|YYm=	NX60ZWlbOC1zMDFOwG0>	MXGyOEBp		MnrQbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk>	M3LxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
SK-N-MC	M1TDNWFxd3C2b4Ppd{BCe3OjeR?=	NHK2ZpAxNTJwNTFOwG0>	M3jQTVI1KGh?		Mm\SbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
WE-68	M{niXGZ2dmO2aX;uJGF{e2G7	NUewRm5vOjBizszN	MYOwMVI1KGh?		M1TseoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>?	M3y3VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
SK-ES-1	MkGxSpVv[3Srb36gRZN{[Xl?	M2ixcVExKM7:TR?=	MUiwMVI1KGh?		M4HGfoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>?	MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
SK-N-MC	MV7GeY5kfGmxbjDBd5NigQ>?	M{HYc\|Mh\|ryP	MmS1NE0zPCCq		NIqzVpJi[3SrdnH0[ZMh[2G\|cHHz[UA{Nzd?	MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
NRK-49F	NFTEO4ZHfW6ldHnvckBCe3OjeR?=	MViw5qCUOsLizszN	M{XvUVM3KGh?		MYnpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iEQsT3TUWEh[W6mIH\pZpJwdmWldHnuJIRwe2ViZHXw[Y5l\W62bIm=	MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F	NYj4VlFwTnWwY4Tpc44hSXO\|YYm=	Ml3ZNQKBmzMEoN88US=>	NHPPfWI{PiCq		NF3RO5lmdmijbnPld{BxcG:\|cHjvdplt[XSrb36gc4YhTUeIUjDhcoQhWESJRmNOtuKh	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F	Ml:zSpVv[3Srb36gRZN{[Xl?	NIrrSVQx6oDVMtMg{txO	NHTDU4Q{PiCq		NVG1UZdO\W6qYX7j[ZMhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w	NYW2VFVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB\|PD;hQi=>
RAW264.7	M3z1eGZ2dmO2aX;uJGF{e2G7	M2[zeFEh\|ryP	NY[3Z2lKPiCq		M1jQTZVxemWpdXzheIV{KHSqZTDy[YR2[2WmIGPJVnQyKHC{b4TlbY4hd3JibWLORUBt\X[nbIOgZpkhcGmpaDDncJVkd3On	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7M{m5OUc,OjV5OUO5PVU9N2F-
MCF10A	M2m4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqwMVIxKM7:TR?=	NV3FOINSOjRiaB?=		NET5bXRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M2DiRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN\|U3Lz5{NUSxNVM2PjxxYU6=
MCF-7	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{T3PFAuOjBizszN	Mnz0NlQhcA>?		M2H6cJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN\|U3RC:jPh?=
T47D	M3LxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYWwMVIxKM7:TR?=	NVnyfHExOjRiaB?=		MkHUdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MoHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN\|U3RC:jPh?=
SKBR3	NGCzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TnNlAuOjBizszN	NH\6b2UzPCCq		Ml24doVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NXjkPGtZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
MDA-MB-231	NVTENosyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD6NoI3OC1{MDFOwG0>	NFL2eVAzPCCq		MXLy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
SUM149	NIf2bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3iyTFAuOjBizszN	M{LZdFI1KGh?		M2PwNZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
HS578T	NU\CTHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3K0cVAuOjBizszN	MYWyOEBp		M2LlUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NWrsV\|kyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
BT20	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYftbGl4OC1{MDFOwG0>	NIWzVGkzPCCq		NXzwbVlIemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NXW0cGR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
A459	NX;Fd2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\SNE0zOCEQvF2=	MVeyOEBp		MmrMdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	M{XVN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN\|U3Lz5{NUSxNVM2PjxxYU6=
HCT116	M2G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXlSoY{OC1{MDFOwG0>	NYq1XoRTOjRiaB?=		MX3y[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk>	NV;K[phnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
Neu	NHnKV\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOxfGMxNTJyIN88US=>	MXqyOEBp		NFy0Uppz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M2fQW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN\|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231	NIW3e2RHfW6ldHnvckBCe3OjeR?=	MnzlOUDPxE1?	M3Xn[VghcA>?		MXPpcoNz\WG\|ZYOgeIhmKG63bXLldkBw\iCjY3nkbYMhfmW\|aXP1cIFzKG:{Z3Hu[Yxt\XN?	M{PaVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN\|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231	M2nzfmZ2dmO2aX;uJGF{e2G7	NUPNdJg5PSEQvF2=	NFfRPI8yPiCq		NV\YdXZqcW6mdXPld{BtgXOxc3;tZYwhdWWvYoLhcoUheGW{bXXhZoltcXqjdHnvci=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MC3T3-E1	MY\GeY5kfGmxbjDBd5NigQ>?	NUHXbVNoOTBizszN	M2PZeFYxKG2rbtMg		MkPWd5VxeHKnc4Pld{B1cGViRlfGMVIue3SrbYXsZZRm\CCxc4Tlc5Bzd3SnZ3XybY4hemWuZXHz[S=>	NXv6XoliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1	NWH0e2pXTnWwY4Tpc44hSXO\|YYm=	MWexNEDPxE1?	M{PrXlYxKG2rbtMg		NF\NfmtifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:\|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36=	NYC4ZZp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1	NXvZWphHTnWwY4Tpc44hSXO\|YYm=	MVexNEDPxE1?	MkPwOlAhdWmwwrC=		M4T4UYF1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?=	NEjmeG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1	NIi3T\|ZHfW6ldHnvckBCe3OjeR?=	NHvpNVMyOCEQvF2=	MkXZOlAhdWmwwrC=		NG\HN2N{fXCycnXzd4V{KHSqZTDCUXAuPC2\|dHnteYxifGWmIG\FS2YhemWuZXHz[S=>	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{W0OFQoRjJ2NEO1OFQ1RC:jPh?=
MC3T3-E1	MlzUSpVv[3Srb36gRZN{[Xl?	MX[xNEDPxE1?	NIPY[5Q3OCCvaX9CpC=>		NE\MfIV{fXCycnXzd4V{KHSqZTDQS2Yz\|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=>	NHXYPWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN\|M{Pid-MkSzN\|M{OzZ:L3G+
MC3T3-E1	NFSzcFdHfW6ldHnvckBCe3OjeR?=	NXzQOWtpOTBizszN	NVHncFdJPjBibXnuxsA>		MUjy[YR2[2W\|IITo[UBRT0Z{zsGtd5RqdXWuYYTl[EBxcG:\|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNm	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{OzN\|YoRjJ2M{OzN\|M3RC:jPh?=
MC3T3-E1	MlHBSpVv[3Srb36gRZN{[Xl?	M4jqNVExKM7:TR?=	M1zLZVYxKG2rbtMg		NFSwZ3BifHSnboXheIV{KHSqZTDQS2Yz\|rFvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBOTUtzL{KgZY5lKFKjZj2x	MoXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{OzN\|YoRjJ2M{OzN\|M3RC:jPh?=
RPE	NXrSVFZ1S2WubDDWbYFjcWyrdImgRZN{[Xl?	MYK1JOK2VQ>?	M1rRSVEhcA>?		NECycndifHSnboXheIV{KE:DzsKtbY5lfWOnZDDk[YNz\WG\|ZTDv[kBk\WyuII\pZYJqdGm2eR?=	NFvrSHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzOlk{QCd-MkSwN\|Y6Ozh:L3G+
9607	NXf4[mF[S2WubDDWbYFjcWyrdImgRZN{[Xl?	MWmxJO69VQ>?	NGqzUG0{PiCq		NU\KWIJ3cW6lcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClb33wZZJm\CC5aYToJI1mdGG2b37pckBidG:wZR?=	Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[5OFkoRjJ\|N{K2PVQ6RC:jPh?=
9607	Mk[4SpVv[3Srb36gRZN{[Xl?	MnqzNUDPxE1?	NHO1PYo{PiCq		MlqzbY5kemWjc3XzJHNKWlRzIHHu[EBl\WO{ZXHz[YQh[WOndInsZZRm\C2yNUOg[ZhxemW\|c3nvci=>	NWnjdndxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlY6PDlpPkKzO\|I3QTR7PD;hQi=>
RPMI.8226	M1rkOWNmdGxiVnnhZoltcXS7IFHzd4F6	MXW3M\|ExKM7:TR?=	MYmyOEBp		M3fleYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NFfnb3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
U266	NXPvXYpyS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWrzTlVSPy9zMDFOwG0>	NH30fHMzPCCq		MlnK[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	NVX3VZdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
MM.1S	MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NEHubmQ4NzFyIN88US=>	MYGyOEBp		MY\k[YNz\WG\|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
KMS12	NELLcpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEHNZXE4NzFyIN88US=>	M2PRRlI1KGh?		Mn;M[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	NGXHTGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
LR5	NHL4[YpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1vWXVcwOTBizszN	NUP5UVRCOjRiaB?=		Mn7P[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1R	NFXXTZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGfD[YU4NzFyIN88US=>	NHLMT\|MzPCCq		NVexUpRi\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6	M{jzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO\|I5Lz5{MUm1NFczQDxxYU6=
Ina6	NWO5Z21TS2WubDDWbYFjcWyrdImgRZN{[Xl?	NILqfYE4NzFyIN88US=>	NXLXbJpLOjRiaB?=		M1;sN4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	M2LiTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO\|I5Lz5{MUm1NFczQDxxYU6=
RPMI-8226	MVzBdI9xfG:\|aYOgRZN{[Xl?	NVTlPHJEPy9zMDFOwG0>	MnLBNlQhcA>?		Moq5bY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM>	M2KzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO\|I5Lz5{MUm1NFczQDxxYU6=
MM.1R	MmntRZBweHSxc3nzJGF{e2G7	NEW3Zlc4NzFyIN88US=>	MWSyOEBp		NXvrOIpvcW6mdXPld{BiKHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJJRp\SCDbn7lfIlvKFZtL2DJ5qiTyqCjcH;weI9{cXN?	MkPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO\|I5RC:jPh?=
H411EC3	M13nS2Z2dmO2aX;uJGF{e2G7	M3S4d\|UxNzFyMDDuUS=>	MVu2JIg>		NULQcJpTcW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w	NFjYeFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlA6Pid-MkGyNVIxQTZ:L3G+
hepatocytes	NGPUeZNHfW6ldHnvckBCe3OjeR?=	NFXXV\|EyOCCwTR?=	MX[2JIg>		NIS0WJRqdmO{ZXHz[ZMhW0mUVEGgZYN1cX[rdImgbY4hfGinIIDy[ZNmdmOnIH;mJHRUSSxiUFXQR2sh[WO2aY\peJktKG2UTlGgcIV3\Wy\|IH;mJHBkczFiYX7kJHBo[zIQsTygZY5lKGWuZY\heIlv\yCpbIXjc5NmKHC{b3T1Z5Rqd25?	NH\EWIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlA6Pid-MkGyNVIxQTZ:L3G+
hepatocytes	MlzSSpVv[3Srb36gRZN{[Xl?	NGW0XZMyOCCwTR?=	MXS2JIg>		M{HZdYlv[3KnYYPld{BJdWelctMgZY5lyqCDY3RCpIdmdmViZYjwdoV{e2mxbh?=	M{LSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
U2OS	NF[5XndHfW6ldHnvckBie3OjeR?=	MU[wMlExKHWP			NILydIFC[3SrdnH0bY9vKG:oIGPJVnQyKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heDV\|IHTlZYNmfHmuYYTpc44hdGW4ZXygZZQhOC5zMDD1US=>	MmTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNE[0NFkoRjF6MES2OFA6RC:jPh?=
A673	NVrTeI5ueUiWUzDhd5NigQ>?				NF6zeGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MXjxTHRUKGG\|c3H5				NVvlZXJ3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	Mom0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M4LxdZFJXFNiYYPzZZk>				NWjrfpEzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M1i1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MWfxTHRUKGG\|c3H5				NFiyZXlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M1jMfJFJXFNiYYPzZZk>				MnWxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NHrBNJFyUFSVIHHzd4F6				NHS5Vo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MXvxTHRUKGG\|c3H5				MmrLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MVLxTHRUKGG\|c3H5				NX7aZoZ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	M3rqO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NHK0VFFyUFSVIHHzd4F6				M2fGcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MX;xTHRUKGG\|c3H5				NXH0fGFueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NHvoc3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	M{nVXJFJXFNiYYPzZZk>				Ml7qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1	26655844
Immunofluorescence	Cathepsin B	26655844
Growth inhibition assay	Cell viability	25411356

In vivo

In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. ^[1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. ^[2]

Protocol (from reference)

Kinase Assay:^[1]	SIRT1 fluorescence polarization assay: In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH₂) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD⁺, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:^[2]	Cell lines: Human vascular endothelial cells (HUVECs) Concentrations: 5 μM Incubation Time: 2 hours Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment. (Only for Reference)
Animal Research:^[1]	Animal Models: Chase-SCID mice with MM.1S cells Dosages: 200 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	38 mg/mL (75.09 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	506.02
Formula	C₂₅H₂₃N₇OS.HCl
CAS No.	1001645-58-4
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

Download SRT1720 HCl SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How can we prepare Srt1720 for in vivo mouse studies?

Answer:
SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):